KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gilead Sciences (GILD) Short-term Investments (2016 - 2025)

Historic Short-term Investments for Gilead Sciences (GILD) over the last 16 years, with Q3 2025 value amounting to $19.0 million.

  • Gilead Sciences' Short-term Investments changed N/A to $19.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.0 million, marking a year-over-year change of. This contributed to the annual value of $1.2 billion for FY2023, which is 2117.16% up from last year.
  • As of Q3 2025, Gilead Sciences' Short-term Investments stood at $19.0 million.
  • Over the past 5 years, Gilead Sciences' Short-term Investments peaked at $1.6 billion during Q2 2021, and registered a low of $19.0 million during Q3 2025.
  • Its 4-year average for Short-term Investments is $1.0 billion, with a median of $1.0 billion in 2022.
  • Per our database at Business Quant, Gilead Sciences' Short-term Investments crashed by 8759.13% in 2021 and then soared by 2117.16% in 2023.
  • Gilead Sciences' Short-term Investments (Quarter) stood at $1.2 billion in 2021, then fell by 17.68% to $973.0 million in 2022, then increased by 21.17% to $1.2 billion in 2023, then plummeted by 98.39% to $19.0 million in 2025.
  • Its last three reported values are $19.0 million in Q3 2025, $69.0 million for Q2 2025, and $1.2 billion during Q4 2023.